Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Long-Term Investments: 2021-2025

Historic Long-Term Investments for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Sep 2025 value amounting to $2.5 million.

  • Rhythm Pharmaceuticals' Long-Term Investments fell 79.38% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 79.38%. This contributed to the annual value of $7.3 million for FY2024, which is 51.16% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Long-Term Investments stood at $2.5 million, which was up 11.40% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Long-Term Investments ranged from a high of $18.4 million in Q1 2022 and a low of $2.2 million during Q2 2025.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Long-Term Investments value was $12.8 million (recorded in 2024), while the average stood at $10.9 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Long-Term Investments spiked by 48.26% in 2022, and later slumped by 82.59% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Long-Term Investments (Quarterly) stood at $11.8 million in 2021, then soared by 40.96% to $16.7 million in 2022, then fell by 9.94% to $15.0 million in 2023, then slumped by 51.16% to $7.3 million in 2024, then plummeted by 79.38% to $2.5 million in 2025.
  • Its Long-Term Investments stands at $2.5 million for Q3 2025, versus $2.2 million for Q2 2025 and $7.1 million for Q1 2025.